-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Downgrades Amicus Therapeutics to Neutral, Lowers Price Target to $14.5

Benzinga·12/19/2025 15:28:23
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska downgrades Amicus Therapeutics (NASDAQ:FOLD) from Overweight to Neutral and lowers the price target from $21 to $14.5.